Biotechs Roaring Back: Do They Sense A Deal?
March 04, 2015 at 14:52 PM EST
Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic lymphocytic leukemia hit $185M and is forecasted to hit the $1B mark in 2015.
